FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

9 Bulk Drugs Proposed for Compounding Exclusion

Federal Register notice: FDA seeks comments on nine bulk drug substances that it is proposing not to allow outsourcing facilities to use in drug compo...

Medical Devices

Concept Medical Breakthrough Status on MagicTouch

FDA grants Concept Medical a breakthrough device designation for MagicTouch AVF, a sirolimus drug-coated balloon catheter for treating stenotic lesion...

Human Drugs

Akari Therapeutics Gains Orphan Status for Nomacopan

FDA grants Akari Therapeutics an orphan drug designation for nomacopan and its use in treating hematopoietic stem cell transplantation-associated thro...

Federal Register

Regulatory Review Period for Pumas Nerlynx

Federal Register notice: FDA determines the regulatory review period for patent extension purposes for Puma Bios Nerlynx (neratinib).

FDA General

Could Sharpless Get Trumped by HHS Asst. Secretary?

The Trump Administration mulls FDA acting commissioner Ned Sharpless time at the agency, and without a nomination to move him into a permanent role hi...

Marketing

OPDP Electronic Submission Webinar

A CDER Office of Prescription Drug Promotion Webinar discusses contents of a recent guidance on providing promotional labeling and advertising materia...

Federal Register

Submissions Extended for Quality Metrics Feedback

Federal Register notice: FDA extends the submission period related to a 6/29 notice on its drug Quality metrics feedback program.

Federal Register

Guide on Cancer Trial Placebo Use & Blinding

Federal Register notice: FDA releases a final guidance on using placebos and allowing blinding in cancer clinical trials.

Human Drugs

AstraZeneca Study Meets Endpoint with Lupus Drug

AstraZeneca says that the Phase 3 TULIP 2 trial for anifrolumab, an investigational drug for treating systemic lupus erythematosus, met its primary en...

Human Drugs

Support, Criticism for Opioid Benefit/Risk Framework Guidance

Stakeholders praise and criticize an FDA draft guidance on a benefit/risk assessment framewok for opioids.